JZP458 closes the asparaginase allergy gap
Blood · 2023
DOI: 10.1182/blood.2022018395 ↗Kurz gefasst
Editorial in der Zeitschrift Blood, 2023. Verfasst von Josep-Maria Ribera. Beteiligte Einrichtung: Josep Carreras Research Institute. Hauptthemen laut MEDLINE: Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug Hypersensitivity, Erwinia. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
In this issue of Blood, Maese et al 1 showed that intramuscular (IM) JZP458 at 25/25/50 mg/m 2 given thrice weekly was an effective and safe alternative for patients with hypersensitivity to Escherichia coli-derived asparaginases (ASPs).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Josep Carreras Research Institute.
ORCID-Profile: Josep-Maria Ribera
Zitieren
APA
Ribera, J. M. (2023). JZP458 closes the asparaginase allergy gap. Blood. https://doi.org/10.1182/blood.2022018395
Vancouver
Ribera JM. JZP458 closes the asparaginase allergy gap. Blood. 2023. doi:10.1182/blood.2022018395
BibTeX
@article{Ribera2023,
author = {Ribera, Josep-Maria},
title = {JZP458 closes the asparaginase allergy gap},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022018395}
}
EUVIMED